Relapsed/Refractory Non-Hodgkin Lymphoma Clinical Trial
Official title:
A Phase 1, Multi-Center, Open-Label, Dose-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BMS-986458, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed/Refractory Non-Hodgkin Lymphomas (R/R NHL)
The purpose of this study is to evaluate the safety, tolerability, drug levels, and preliminary biological and clinical activity of BMS-986458 as a single agent and in combination with anti-lymphoma agents in participants with relapsed/refractory non-Hodgkin Lymphoma.
| Status | Recruiting |
| Enrollment | 273 |
| Est. completion date | October 28, 2028 |
| Est. primary completion date | October 28, 2027 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - Participants = 18 years of age with R/R NHL (including DLBCL [ie, DLBCL not otherwise specified (NOS) and diffuse large B-Cell lymphoma/high-grade B-Cell lymphoma with MYC and BCL2 rearrangements], and FL): - For R/R DLBCL (de novo) and FL 3b: following at least 2 prior lines of therapy (eg, first-line combination chemotherapy regimen containing rituximab, anthracycline, an alkylating agent, and steroids and at least one additional treatment). - For R/R DLBCL (transformed lymphoma): following at least 2 prior lines of therapy which must have been administered after transformation. - For R/R FL (except for FL 3b): following at least 2 prior lines of therapy and meeting treatment criteria at the time of enrollment based on investigator´s assessment. - Participant must have measurable disease (defined by at least one FDG-avid lesion for FDG-avid disease and one bi-dimensionally measurable disease on cross sectional imaging by computed tomography or magnetic resonance imaging with at least one lesion > 1.5 cm in the transverse diameter). - Participants must accept and follow pregnancy prevention plan. Exclusion Criteria: - Participants must not have an Eastern Cooperative Oncology Group (ECOG)22 performance status = 3. - Participants with an inability to comply with listed restrictions, precautions and prohibited treatments. - Participants must not have prior CAR-T, Cereblon-modulating drug or radiotherapy = 4 weeks, systemic anticancer treatment = 5 half-lives or 4 weeks, allogeneic SCT = 6 months or autologous SCT = 3 months prior to study intervention initiation. - Participants must not have any condition, including significant acute or chronic medical illness, active or uncontrolled infection, or the presence of laboratory abnormalities, that places participants at unacceptable risk if participating in this study. - Participants must not have known or suspected central nervous system involvement. |
| Country | Name | City | State |
|---|---|---|---|
| France | Hopital Claude Huriez - CHU de Lille | Lille | Nord |
| France | CHU SAINT ELOI-Département d'Hématologie Clinique | Montpellier | |
| France | Institut Claudius Regaud | Toulouse | |
| France | Gustave Roussy | Villejuif | Paris |
| Netherlands | University Medical Center Groningen | Groningen | |
| Netherlands | Maastricht UMC+ | Maastricht | Limburg |
| Spain | Hospital Universitario Fundación Jiménez Díaz | Madrid | |
| Spain | Hospital Universitario Virgen de la Victoria | Málaga | Andalucía |
| Spain | Clinica Universidad de Navarra | Pamplona | Navarra |
| Spain | Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca | Salamanca | |
| Switzerland | Ospedale Regionale Bellinzona e Valli | Bellinzona | Ticino |
| Switzerland | Hôpitaux Universitaire de Genève | Genève | |
| United States | Dana-Farber Cancer Institute | Boston | Massachusetts |
| United States | City of Hope Comprehensive Cancer Center | Duarte | California |
| United States | Local Institution - 0047 | Lake Success | New York |
| United States | Memorial Sloan Kettering Cancer Center | New York | New York |
| Lead Sponsor | Collaborator |
|---|---|
| Bristol-Myers Squibb |
United States, France, Netherlands, Spain, Switzerland,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Number of participants with adverse events (AEs) | Up to 2 years and 1 month | ||
| Primary | Number of participants with serious adverse events (SAEs) | Up to 2 years and 1 month | ||
| Primary | Number of participants with AEs meeting protocol-defined dose-limiting toxicity (DLT) criteria | Up to 2 years and 1 month | ||
| Primary | Number of participants with AEs leading to discontiunation | Up to 2 years and 1 month | ||
| Primary | Number of participants with AEs leading to death | Up to 2 years and 1 month | ||
| Secondary | Maximum concentration (Cmax) | Up to 4 months | ||
| Secondary | Time of maximum concentration (Tmax) | Up to 4 months | ||
| Secondary | Area under the plasma concentration-time curve (AUC(0-T)) | Up to 4 months | ||
| Secondary | Number of participants with an overall response rate (ORR) according to the Lugano response criteria for Non-Hodgkin Lymphoma | Up to 2 years | ||
| Secondary | Duration of response (DOR) | Up to 2 years | ||
| Secondary | Time to response (TTR) | Up to 2 years | ||
| Secondary | Progression-free survival (PFS) | Up to 2 years | ||
| Secondary | Overall survival (OS) | Up to 2 years |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05320640 -
Study of Chidamide, Decitabine and Immune Checkpoint Inhibitors in R/R NHL and Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Terminated |
NCT03403725 -
MEN1309 I.v. Infusion in Pts With CD205-positive Metastatic Solid Tumors and Relapsed or Refractory NHL Ph I Study
|
Phase 1 | |
| Recruiting |
NCT05880043 -
A Study of GIC-102 (Allogeneic Natural Killer Cells) in Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, and Multiple Myeloma
|
Phase 1 |